Teprotumumab 是一种阻断 IGF-1 受体 (IGF-1R) 的人单克隆抗体。Teprotumumab 与 IGF-1R 的细胞外 α-亚基结构域配体结合。Teprotumumab 抑制纤维细胞中的 TSH 和 IGF-1 作用。Teprotumumab 可降低 TSH 依赖性 IL-6 和 IL-8 的表达和 Akt 的磷酸化。Teprotumumab 可用于甲状腺相关眼病的研究。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of Akt phosphorylation. Teprotumumab can be used for troid-associated ophthalmopat research[1].
Teprotumumab (0-500 μg/mL, 12 h) attenuates the actions of both IGF-1 and TSH in fibrocytes. IGF-1R and TSHR mRNA abundance is unaffected by Teprotumumab after 24 hours[1].
[1]. Chen H, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-40.
DMNPE-caged ATP diammonium salt
¥3870.00 ¥4837.00
没有评价数据